Non-small Cell Lung Cancer in South Wales: Are Exon 19 Deletions and L858R Different?

Anticancer Res. 2016 Aug;36(8):4267-71.


Background/aim: In advanced non-small cell lung cancer (NSCLC), the epidermal growth factor receptor (EGFR) mutations L858R and exon 19 deletion (del19) predict response to EGFR tyrosine kinase inhibitors (TKIs). Trials have suggested a differential response to the second-generation EGFR TKI afatinib in favour of del19. We investigated whether this differential response is observed in clinical practice.

Materials and methods: Retrospective demographic, treatment and outcome data were collected on patients with: stage III/IV NSCLC and either del19 or L858R, receiving an EGFR TKI as first-line treatment.

Results: There was no significant difference in overall survival (OS) between del19 (648 days, 95% confidence interval (CI)=461-835) and L858R (813 days, 95%CI=387-1,238), (p=0.616), or in duration of therapy between del19 (365 days, 95% CI=192-538) and L858 (428 days, 95% CI=263-593), (p=0.928).

Conclusion: Patients with exon del19 did not have a significantly longer OS with first-generation TKIs.

Keywords: EGFR mutation; L858R; NSCLC; advanced non-small cell lung cancer; exon 19 deletion.

MeSH terms

  • Adult
  • Afatinib
  • Aged
  • Aged, 80 and over
  • Carcinoma, Non-Small-Cell Lung / epidemiology*
  • Carcinoma, Non-Small-Cell Lung / genetics*
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Disease-Free Survival
  • ErbB Receptors / genetics*
  • Exons / genetics
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Protein Kinase Inhibitors / therapeutic use
  • Quinazolines / therapeutic use
  • Retrospective Studies
  • Sequence Deletion / genetics
  • Wales / epidemiology


  • Protein Kinase Inhibitors
  • Quinazolines
  • Afatinib
  • EGFR protein, human
  • ErbB Receptors